Background
Heart failure (HF) is a chronic clinical syndrome involving up to 6.5 million people in Europe. It is the leading cause of hospitalisation in adults, yielding a healthcare cost of 17 billion euro/year. The mortality is comparable/superior to several type of cancers in the EU perspective, reaching 70% at 5-year in the advanced stages of HF. European Society of Cardiology (ESC) recently updated the HF guidelines to incorporate two new drug classes showing a dramatic reduction of hospitalisation and death in large scale randomised clinical trials (RCT) involving patients with heart failure and reduced ejection fraction (HFrEF).
0
6.5 milion involved people in Europe with heart failure and reduced ejection fraction
70%
Mortality
The conceptual framework of BIOTOOL-CHF will be developed into three main PHASES:
1-Discovery
BIOTOOL-CHF will discover a multiparametric biomarker-based score, integrating clinical profiles, novel and standard laboratory assays, to define independent clusters of congestion predicting congestion-related events, including worsening heart failure as well as toxicities related to excessive diuretic therapy
2-Development
In this phase BIOTOOL-CHF will direct the activities towards the development of two products of potential industrial exploitation
3-Validation
BIOTOOL-CHF will provide clinical validation of the biomarkers-guided approach to manage diuretic therapy by a prospective randomised study comparing standard of care with decision-making tool guided approach
